# CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

> **NCT02675946** · PHASE1 · UNKNOWN · sponsor: **Curegenix Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Solid Tumors
- GI Cancer

## Interventions

- **DRUG:** CGX1321
- **DRUG:** Pembrolizumab
- **DRUG:** encorafenib
- **DRUG:** cetuximab

## Key facts

- **NCT ID:** NCT02675946
- **Lead sponsor:** Curegenix Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02
- **Primary completion:** 2023-03
- **Final completion:** 2023-03
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675946, "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02675946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*